I’m in the mood for some serious “cut and paste” this morning! So I’ve gone back to Tuesday’s announcement to cut and paste and rework it.
….intracutaneous islet grafts can be monitored in vivo, enable topical immunosuppression and removed in toto, thus creating an attractive site for gene modified, xenogeneic- and stem-cell-derived ICT.
Professor Coates said… the results show an exciting new opportunity for the NovoSorb technology in cell therapies as a delivery vehicle.
Professor Greenwood, who conceived of NovoSorb BTM, says that,… The results of our trials confirms that the NovoSorb technology has the potential to be a game changer in the cell therapy space.
PolyNovo has been supplying the NovoSorb BTM material to Beta Cell at no cost during their product development program and Beta Cell has successfully established and developed collaborations with major cell therapy players such as the global leader in T1D based in Denmark (Novo Nordisk, my note), Breakthrough T1D based in New York, JDRF Australia and the Garvan Institute in Sydney.
PolyNovo Chairman David Williams said… These are very exciting results, and a red letter day potentially creating a new and distinct silo for the PolyNovo business; one in Wound Care and related uses, and another in Cell Delivery….…we are extremely excited about the use of PolyNovo as a delivery device in cell therapies. Professors Coates and Greenwood have articulated the properties of our technology that should make it attractive to other cell therapy companies.
Going forward, PolyNovo and Beta Cell are in collaboration discussions to accelerate research and development pathways to ensure PolyNovo’s technology can play a major role in the cell therapy market space which is estimated to be USD $34 Billion by 2034. Professors Coates and Greenwood are subject matter experts and will guide PolyNovo’s involvement.
So, we have learned that Novo Nordisk supplied the islet cells used in the Beta Cell Technologies research study. The question is, does Novo Nordisk have broader interest in cell therapies?
Here’s the answer from their website, using some more beloved “cut and paste”.
At Novo Nordisk, we aspire to write the future of cell therapy.
Our focus positions us to pioneer treatments that may be uniquely qualified to change the lives of people living with serious chronic diseases. We are working to develop treatments for Parkinson's disease, chronic heart failure and type 1 diabetes that have the potential to halt disease progression — or even reverse it.
By collaborating with the best in the world, we aim to accelerate the research that’s needed to develop transformative cell therapies faster for those living with serious chronic diseases…
Novo Nordisk is partnering with global innovators to accelerate the development of therapeutic breakthroughs at scale….
By partnering with academia, biotechs, and device experts, we can share knowledge, data, and capabilities in ways that bring us closer to developing potential cell therapies for people living with serious chronic disease..
Together with leading research universities around the world, we have been able to transform stem cells into glucose-sensing, insulin-secreting beta cells, just like those produced in the pancreas of a healthy person. In animal studies, these transformed stem cells successfully cured mice with type 1 diabetes.
We have made significant steps forward, and continue to work on the remaining challenges.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)